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Abstract. During the drug design process, one must develop a molecule,
which structure satisfies a number of physicochemical properties. To
improve this process, we introduce Mol-CycleGAN – a CycleGAN-based
model that generates compounds optimized for a selected property, while
aiming to retain the already optimized ones. In the task of constrained
optimization of penalized logP of drug-like molecules our model signifi-
cantly outperforms previous results.
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1 Introduction
The principal goal of the drug design process is to find new chemical compounds
that are able to modulate the activity of a given target in a desired way [13].
However, finding such molecules in the high-dimensional chemical space of all
molecules without any prior knowledge is nearly impossible. In silico methods
have been introduced to leverage the existing knowledge, thus forming a new
branch of science - computer-aided drug design (CADD) [1,12].
The recent advancements in deep learning have encouraged its application in
CADD [4]. One of the main approaches is de novo design, that is using generative
models to propose new molecules that are likely to possess the desired properties
[3,5,15,17].
In the center of our interest are the hit-to-lead and lead optimization phases
of the compound design process. Their goal is to optimize the drug candidates
identified in the previous steps in terms of the desired activity profile and their
physicochemical and pharmacokinetic properties.
To address this problem, we introduce Mol-CycleGAN – a generative
model based on CycleGAN [19]. Given a starting molecule, it generates a struc-
turally similar one but with a desired characteristic. We show that our model
generates molecules that possess desired properties while retaining their struc-
tural similarity to the starting compound. Moreover, thanks to employing graph-
based representation, our algorithm always returns valid compounds.
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To assess the model’s utility for compound design we evaluate its ability to
maximize penalized logP property. Penalized logP is chosen because it is often
selected as a testing ground for molecule optimization models [7,18], due to
its relevance in the drug design process. In the optimization of penalized logP
for drug-like molecules our model significantly outperforms previous results. To
the best of our knowledge, Mol-CycleGAN is the first approach to molecule
generation that uses the CycleGAN architecture.
2 Mol-CycleGAN
Mol-CycleGAN is a novel method of performing compound optimization by
learning from the sets of molecules with and without the desired molecular
property (denoted by the sets X and Y ). Our approach is to train a model to
perform the transformation G : X → Y (and F : Y → X) which returns the
optimized molecules. In the context of compound design X (Y ) can be, e.g., the
set of inactive (active) molecules.
To represent the sets X and Y our approach requires an embedding of
molecules which is reversible, i.e. enables both encoding and decoding of
molecules. For this purpose we use the latent space of Junction Tree Varia-
tional Autoencoder (JT-VAE) [7] – we represent each molecule as a point in the
latent space, given by the mean of the variational encoding distribution [9]. This
approach has the advantage that the distance between molecules (required to
calculate the loss function) can be defined directly in the latent space.
Our model works as follows: (i) we define the sets X and Y (e.g., inac-
tive/active molecules); (ii) we introduce the mapping functions G : X → Y and
F : Y → X; (iii) we introduce discriminator DX (and DY ) which forces the
generator F (and G) to generate samples from a distribution close to the distri-
bution of X (or Y ). The components F , G, DX , and DY are modeled by neural
networks (see subsect. 2.1 for technical details).
The main idea is to: (i) take the prior molecule x without a specified feature
(e.g. activity) from set X, and compute its latent space embedding; (ii) use the
generative neural network G to obtain the embedding of molecule G(x), that
has this feature (as if the G(x) molecule came from set Y ) but is also similar to
the original molecule x; (iii) decode the latent space coordinates given by G(x)
to obtain the optimized molecule. Thereby, the method is applicable in lead
optimization processes, as the generated compound G(x) remains structurally
similar to the input molecule.
To train the Mol-CycleGAN we use the following loss function:
L(G,F,DX ,DY ) = LGAN(G,DY ,X, Y ) + LGAN(F,DX , Y,X)
+ λ1Lcyc(G,F ) + λ2Lidentity(G,F ),
(1)
and aim to solve
G∗, F ∗ = arg min
G,F
max
DX ,DY
L(G,F,DX ,DY ). (2)
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We use the adversarial loss introduced in LS-GAN [11]:
LGAN(G,DY ,X, Y ) =
1
2
Ey∼pdata(y)[(DY (y)−1)2]+
1
2
Ex∼pdata(x)[(DY (G(x)))
2],
(3)
which ensures that the generator G (and F ) generates samples from a distribu-
tion close to the distribution of Y (or X).
The cycle consistency loss:
Lcyc(G,F ) = Ey∼pdata(y)[‖G(F (y)) − y‖1] + Ex∼pdata(x)[‖F (G(x)) − x‖1], (4)
reduces the space of possible mapping functions, such that for a molecule x from
set X, the GAN cycle brings it back to a molecule similar to x, i.e. F (G(x)) is
close to x (and analogously G(F (y)) is close to y).
Finally, to ensure that the generated (optimized) molecule is close to the
starting one, we use the identity mapping loss [19]:
Lidentity(G,F ) = Ey∼pdata(y)[‖F (y) − y‖1] + Ex∼pdata(x)[‖G(x) − x‖1], (5)
which further reduces the space of possible mapping functions and prevents the
model from generating molecules that lay far away from the starting molecule
in the latent space of JT-VAE.
In our experiments, we use the hyperparameters λ1 = 0.3 and λ2 = 0.1. Note
that these parameters control the balance between improvement in the optimized
property and similarity between the generated and the starting molecule.
2.1 Workflow
We conduct experiments to test if the proposed model is able to generate
molecules that are close to the starting ones and possess increased octanol-water
partition coefficient (logP) penalized by the synthetic accessibility (SA) score.
We optimize penalized logP, while constraining the degree of deviation from the
starting molecule. The similarity between molecules is measured with Tanimoto
similarity on Morgan Fingerprints [14].
We use the ZINC-250K dataset used in similar studies [7,10] which contains
250000 drug-like molecules extracted from the ZINC database [16]. The sets
Xtrain and Ytrain are random samples of size 80000 from ZINC-250K, where the
compounds’ penalized logP values are below and above the median, respectively.
Xtest is a separate, non-overlapping dataset, consisting of 800 molecules with the
lowest values of penalized logP in ZINC-250K.
All networks are trained using the Adam optimizer [8] with learning rate
0.0001, batch normalization [6] and leaky-ReLU with α = 0.1. The models are
trained for 300 epochs. Generators are built of four fully connected residual
layers, with 56 units. Discriminators are built of 7 dense layers of the following
sizes: 48, 36, 28, 18, 12, 7, 1 units.
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Table 1. Results of the constrained optimization for JT-VAE [7], Graph Convolutional
Policy Network (GCPN) [18] and Mol-CycleGAN.
δ JT-VAE GCPN Mol-CycleGAN
Improvement Similarity Improvement Similarity Improvement Similarity
0 1.91 ± 2.04 0.28 ± 0.15 4.20 ± 1.28 0.32 ± 0.12 8.30 ± 1.98 0.16 ± 0.09
0.2 1.68 ± 1.85 0.33 ± 0.13 4.12 ± 1.19 0.34 ± 0.11 5.79 ± 2.35 0.30 ± 0.11
0.4 0.84 ± 1.45 0.51 ± 0.10 2.49 ± 1.30 0.47 ± 0.08 2.89 ± 2.08 0.52 ± 0.10
0.6 0.21 ± 0.75 0.69 ± 0.06 0.79 ± 0.63 0.68 ± 0.08 1.22 ± 1.48 0.69 ± 0.07
3 Results
We optimize the penalized logP under the constraint that the similarity between
the original and the generated molecule is higher than a fixed threshold (denoted
as δ). This is a realistic scenario in drug discovery, where the development of
new drugs usually starts with known molecules such as existing drugs [2].
We maximize the penalized logP coefficient and use the Tanimoto similarity
with the Morgan fingerprint to define the threshold of similarity. We compare
our results with previous similar studies [7,18].
In our optimization procedure, each molecule is fed into the generator to
obtain the ‘optimized’ molecule G(x). The pair (x,G(x)) defines an ’optimization
path’ in the latent space of JT-VAE. To be able to make a comparison with the
previous research [7] we start the procedure from the 800 molecules with the
lowest values of penalized logP in ZINC-250K and then we decode molecules
from 80 points along the path from x to G(x) in equal steps. From the resulting
set of molecules we report the molecule with the highest penalized logP score
Fig. 1. Molecules with the highest improvement of the penalized logP for δ ≥ 0.6.
In the top row we show the starting and in the bottom row the optimized molecules.
Upper row numbers indicate Tanimoto similarities between the starting and the final
molecule. The improvement in the score is given below the generated molecules.
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Fig. 2. Evolution of a selected exemplary molecule during constrained optimization.
We only include the steps along the path where a change in the molecule is introduced.
We show values of penalized logP below the molecules.
that satisfies the similarity constraint. In the task of optimizing penalized logP
of drug-like molecules, our method significantly outperforms the previous results
in the mean improvement of the property (Table 1) and achieves a comparable
mean similarity in the constrained scenario (for δ > 0).
Molecules with highest improvement of logP are presented in Fig. 1 with the
improvement given below the generated molecules.
Figure 2 shows starting and final molecules, together with all molecules gen-
erated along the optimization path and their values of penalized logP.
4 Conclusions
In this work, we introduce Mol-CycleGAN – a new model based on CycleGAN
which can be used for the de novo generation of molecules. The advantage of
the proposed model is the ability to learn transformation rules from the sets
of compounds with desired and undesired values of the considered property.
The model can generate molecules with desired properties, as shown on the
example of penalized logP. The generated molecules are close to the starting
ones and the degree of similarity can be controlled via a hyperparameter. In the
task of constrained optimization of drug-like molecules our model significantly
outperforms previous results.
The code used to produce the reported results can be found online at https://
github.com/ardigen/mol-cycle-gan.
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Open Access This chapter is licensed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/),
which permits use, sharing, adaptation, distribution and reproduction in any medium
or format, as long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license and indicate if changes were
made.
The images or other third party material in this chapter are included in the chapter’s
Creative Commons license, unless indicated otherwise in a credit line to the material. If
material is not included in the chapter’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder.
